REGIMEN |
STUDY GROUPS
|
Total AV block ( QRS complex duration, ventricular frequency) |
Ventricular tachycardia(torsades de pointes) (QRS complex duration, heart frequency) |
THERAPEUTIC
Medication at 90min after fursemide |
BASELINE before medication (per 5min.) |
5–60 min. after
medication |
BASELINE before
Medication (per 5 min.) |
5–60 min. after
medication |
QRS complex duration (msec) |
Ventricular frequency (beats/min) |
QRS complex duration (msec) |
Ventricular frequency (beats/min) |
QRS complex duration (msec) |
Ventricular frequency (beats/min) |
QRS complex duration (msec) |
Ventricular frequency (beats/min) |
CONTROL
(SALINE 5ml/kg) |
31.7±1.4 |
99.4±2.1 |
32.1±1.3 ¥ |
93.6±4.1 ¥ |
30.9±1.8 |
289.8±4.1 |
34.4±2.4 ¥ |
284.1±3.6 ¥ |
BPC 157 10µg/kg ip |
32.1±1.3 |
97.2±4.1 |
23.9±2.1 †*¥ |
90.1±2.3 ¥ |
31.5±2.1 |
282.3±3.7 |
27.5±3.1 ¥ |
261.3±3.7 †*¥ |
BPC157 10ng/kg |
30±1.1 |
93±3.2 |
25±1.1*¥ |
95±2.5¥ |
33.1±1.1 |
292±4.0 |
24.5±2.0¥ |
250.1±2.1†*¥ |
L-NAME |
31.7±1.2 |
98.5±2.7 |
35.7±2.8 ¥ |
91.6±4.1 ¥ |
32.1±1.5 |
284.1±3.5 |
35.9±2.1 ¥ |
289.4±3.2 ¥ |
L-NAME + BPC 157 |
31.9±1.5 |
99.2±3.2 |
27.3±1.8 †*¥ |
100.1±2.3 ¥ |
31.5±1.1 |
289.8±4.1 |
32.1±2.4 ¥ |
271.8±4.1 †*¥ |
L-arginine |
31.1±1.8 |
96.9±3.6 |
28.9±2.5¥ |
94.9±3.9 ¥ |
32.1±1.3 |
288.3±3.1 |
30.4±2.3 ¥ |
279.3±3.7 ¥ |
L-arginine + BPC 157 |
31.8±1.4 |
97.6±2.1 |
22.9±1.9 †*¥ |
102.6±1.2 ¥ |
32.4±1.9 |
285.4±3.8 |
28.6±1.5 ¥ |
267.4±2.9 †*¥ |
L-NAME + Larginine |
32.1±1.3 |
99.5±2.7 |
23.2±3.1 †*¥ |
96.2±3.4 ¥ |
31.8±1.7 |
291.2±3.3 |
34.5±2.5 ¥ |
286.2±3.9 ¥ |
L-NAME + Larginine + BPC 157 |
32.2±1.6 |
98.3±3.2 |
24.3±2.4 †*¥ |
102.3±2.5 ¥ |
31.9±2.3 |
289.3±2.9 |
30.1±2.8 ¥ |
269.3±3.7 †*¥ |
PROPHYLACTIC
Medication at 15min before furosemide |
STUDY GROUPS
|
Total AV block ( QRS complex duration. ventricular frequency) |
Ventricular tachycardia(torsades de pointes) (QRS complex duration. heart frequency) |
BASELINE 90min after furosemide appplication |
95–150 min. after
furosemide appplication |
BASELINE 90min after furosemide appplication |
95–1500 min. after
furosemide appplication |
QRS complex duration (sec) |
Ventricular frequency (beats/min) |
QRS complex duration (sec) |
Ventricular frequency (beats/min) |
QRS complex duration (sec) |
Ventricular frequency (beats/min) |
QRS complex duration (sec) |
Ventricular frequency (beats/min) |
BPC 157 10µg/kg |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
BPC 157 10ng/kg |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
L-NAME |
35.7±1.8 |
99.4±1.4 |
42.1±2.2 ¥ |
86.6±5.3 ¥ |
38.9±1.8 |
296.8±1.1 |
48.4±2.4 ¥ |
277.1±5.6 ¥ |
L-NAME + BPC 157 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
L-arginine |
26.4.±1.5 |
112.4±4.1 |
36.1±2.1 ¥ |
105.6±6.2 ¥ |
40.9±1.8 |
304.8±6.1 |
41.1±3.3 ¥ |
296.1±3.1 ¥ |
L-arginine + BPC 157 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
L-NAME + L-arginine |
33.2±1.0 |
100.4±3.6 |
36.1±1.1 ¥ |
98.4±2.1 ¥ |
33.4±2. |
296.2±3.5 |
38.0±2.0 ¥ |
288.1±5.0 ¥ |
L-NAME + L-arginine + BPC 157 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |